ATP-sensitive K+ channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation.
Adenosine A1 receptor stimulation increases myocardial resilience to ischaemia many hours later but the mechanism of protection is unclear. We hypothesized that A1 receptor-induced delayed cardioprotection is mediated by KATP channel opening. Rabbits were pretreated with saline or the selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA), 0.1 mg/kg i.v. After 24 h, they were anaesthetized and subjected to 30 min left coronary artery occlusion (CAO) and 120 min reperfusion. Twenty minutes before CAO, either glibenclamide 0.3 mg/kg, sodium 5-hydroxydecanoate (5-HD) 5 mg/kg, or a corresponding volume of vehicle solution were given i.v. Infarct size as a percentage of ischaemic risk volume (I/R%) was assessed by triphenyltetrazolium. In the absence of either glibenclamide or 5-HD, CCPA pretreatment resulted in significant limitation of infarction (I/R 23.4+/-3.3%vs 39.6+/-2.6% in saline pretreated animals, P<0.01). Administration of glibenclamide before CAO abolished this delayed protective effect of CCPA (I/R 37.4+/-4. 7%), as did 5-HD (I/R 48.8+/-3.7%). Neither glibenclamide nor 5-HD significantly modified I/R in saline pretreated animals. Risk volume was similar in all groups (0.8-1.1 cm3). Systemic haemodynamic variables were not markedly different between any of the groups immediately before or during the ischaemia-reperfusion protocol. Thus, delayed protection following transient A1 receptor activation was abolished by pre-ischaemic treatment with either glibenclamide or 5-HD, providing pharmacological evidence that KATP channel opening mediates A1 agonist-induced delayed myocardial protection. The inhibitory effect of 5-HD suggests specific involvement of mitochondrial KATP but the mechanisms of sub-acute regulation of KATP function following A1 receptor stimulation remain to be determined.
Baxter
G F
GF
The Hatter Institute for Cardiovascular Studies, University College London Hospitals & Medical School, London, UK.
Yellon
D M
DM
D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003652:Decanoic Acids / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D006439:Hemodynamics / Q000187:drug effects; D006880:Hydroxy Acids / Q000494:pharmacology; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology; D015221:Potassium Channels / Q000187:drug effects*; D058906:Purinergic P1 Receptor Agonists; D011817:Rabbits; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D001786:Blood Glucose; D003652:Decanoic Acids; D006880:Hydroxy Acids; D015221:Potassium Channels; D058906:Purinergic P1 Receptor Agonists; C052853:5-hydroxydecanoic acid; D000255:Adenosine Triphosphate; D005905:Glyburide